Clear All
773 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
C9064 Mitomycin pyelocalyceal instillation Jelmyto 1mg Chemotherapy Antitumor Antibiotic Alkylating Agent/Mitomycin No 2020 Oct 1, 2020 Jan 1, 2021 No Longer Used
C9284 Ipilimumab Yervoy 1mg Immunotherapy Checkpoint Inhibitor CTLA-4 No 2011 Jul 1, 2011 Dec 31, 2011 No Longer Used
J9281 Mitomycin Pyelocalyceal Instillation Jelmyto 1mg Chemotherapy Antitumor Antibiotic Alkylating Agent/Mitomycin No 2020 Jan 1, 2021 In Use
C9303 Zolbetuximab-clzb Vyloy 1mg Immunotherapy Monoclonal Antibody CLDN18.2 No 2024 Mar 26, 2025 Jul 9, 2025 No Longer Used
J3263 Toripalimab-tpzi Loqtorzi 1mg Immunotherapy Checkpoint Inhibitor PD-1 No 2023 Jun 10, 2024 In Use
C9307 Linvoseltamab-gcpt Lynozyfic 1mg Immunotherapy Bispecific Antibody BCMA, CD3 No 2025 Jan 1, 2026 In Use
J1323 Elranatamab-bcmm Elranatamab-bcmm 1mg Immunotherapy Monoclonal Antibody BCMA, CD3 No 2023 Apr 17, 2024 In Use
J9063 Mirvetuximab soravtansine Elahere 1mg Immunotherapy Drug Antibody Conjugate FR-alpha, DM4 No 2022 Jul 11, 2023 In Use
J9350 Mosunetuzumab-axgb Lunsumio 1mg Immunotherapy Monoclonal Antibody CD20, CD3 No 2022 Jul 11, 2023 In Use
J9342 Thiotepa (not otherwise specified) Thiotepa 1mg Chemotherapy Alkylating Agent Nitrogen Mustard /Ethylenimine No 2001 Jul 9, 2025 In Use
J9011 Datopotamab Deruxtecan Datroway 1mg Immunotherapy Drug Antibody Conjugate Topoisomerase I, TROP2 No 2025 Sep 8, 2025 In Use
J1456 Fosaprepitant (Teva) Fosaprepitant (Teva) 1mg Ancillary Therapy Antiemetic Substance P/Neurokinin 1 No 2019 Dec 21, 2022 In Use
J1434 Fosaprepitant Focinvez 1mg Ancillary Therapy Antiemetic Substance P/Neurokinin 1 No 2023 Apr 17, 2024 In Use
J9354 Ado-Trastuzumab Emtansine Kadcyla 1mg Immunotherapy Drug Antibody Conjugate HER2 No 2013 Jan 1, 2014 In Use
C9145 Aprepitant Aponvie 1mg Ancillary Therapy Antiemetic Substance P/Neurokinin 1 No 2023 Mar 17, 2023 In Use
Q5159 Denosumab-dssb Ospomyv, Xbryk 1mg Immunotherapy Monoclonal Antibody RANKL No 2025 Sep 8, 2025 In Use
J9259 Paclitaxel (American Regent) Paclitaxel (American Regent) 1mg Chemotherapy Antimitotic Agent Taxane No 2023 Jul 11, 2023 Dec 17, 2024 No Longer Used
NA Anagrelide Agrylin 1mg Ancillary Therapy Platelet-Reducing Agent PDE-3 Inhibitor Yes 1997 In Use
C9165 Elranatamab-bcmm Elrexfio 1mg Immunotherapy Monoclonal Antibody BCMA, CD3 No 2023 Dec 7, 2023 Apr 17, 2024 No Longer Used
C9078 Trilaciclib Cosela 1mg Chemotherapy Cyclin Dependent Kinase Inhibitor CDX 4/6 No 2021 Jul 23, 2021 Sep 27, 2021 No Longer Used
J9326 Telisotuzumab vedotin-tllv Emrelis 1mg Immunotherapy Drug Antibody Conjugate c-MET No 2025 Jan 1, 2026 In Use
J1952 Leuprolide Mesylate Camcevi 1mg Hormonal Therapy GnRH Agonist No 2021 Jan 26, 2022 In Use
C9174 Datopotamab Deruxtecan Datroway 1mg Immunotherapy Drug Antibody Conjugate Topoisomerase I No 2025 Jul 9, 2025 Sep 8, 2025 In Use
J9058 Bendamustine (Apotex) Bendamustine (Apotex) 1mg Chemotherapy Alkylating Agent Nitrogen Mustard No 2023 Jul 11, 2023 Sep 14, 2024 No Longer Used
C9170 Tarlatamab-dlle, 1 mg IMDELLTRA 1mg Immunotherapy T Cell Receptor (TCR) DLL3, CD3 No 2024 Sep 11, 2024 Dec 17, 2024 No Longer Used
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.